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Ciprian Chira1,2, Guila Delouya1,2, Sandra Larrivée2, Jean-Francois Carrier1,2 and Daniel Taussky1,2*Abstract
Background: To determine prostate volume (Pvol) changes at 3 different time points during the course of I125
permanent seed brachytherapy (PB). To assess the impact of these changes on acute urinary retention (AUR) and
dosimetric outcome.
Methods: We analyzed 149 hormone-naïve patients. Measurements of the prostate volume were done using three-
dimensional transrectal ultrasound (3D-TRUS) in the operating room before insertion of any needle (V1), after the
insertion of 2 fixation needles with a harpoon (V2) and upon completion of the implant (V3). The quality of the
implant was analyzed with the D90 (minimum dose in Grays received by 90% of the prostate volume) at day 30.
Results: Mean baseline prostate volume (V1) was 37.4 ± 9.6 cc. A volume increase of >5% was seen in 51%
between V1-V2 (mean = 2.5 cc, p < 0.01), in 42% between V2-V3 (mean = 1.9 cc, p < 0.01) and in 71% between
V1-V3 (mean = 4.5 cc, p < 0.01). Pvol changes caused by insertion of the fixation needles were not statistically
different than those caused by the implant itself (p = 0.23).
In multivariate linear regression analysis, baseline Pvol is predictive of Pvol changes between V2 and V1 and V3 and
V1 but not between V3 and V2. The extent of prostate swelling had an influence on D90. An increase of 10% in
prostate volume between V1 and V2 results in an increase of D90 at Day 30 by 11.7%. Baseline Pvol (V1) was the
only predictor of the duration of urinary retention in both univariate and multivariate (p = 0.04) regression analysis.
Conclusions: A large part of intraoperative swelling occurs already after the insertion of the fixation needles. This
early prostate swelling predicts for D90 but not for AUR.
Keywords: Prostate, Permanent seed brachytherapy, Intra-operative edemaBackground
Prostate swelling associated with I125 permanent seed
brachytherapy (PB) is considered a risk factor for sub-
optimal post implant dosimetry [1], decrease probability
of tumor control [2] and higher toxicity rates [3]. The
time course of this phenomenon has been previously
described. But different imaging modalities (CT, MRI,
TRUS) were used and compared to each other and some* Correspondence: daniel.taussky.chum@ssss.gouv.qc.ca
1Departement of Radiation Oncology, Centre hospitalier de l’Université de
Montréal (CHUM), Notre-Dame Hospital, 1560 Sherbrooke St. E., Montreal, QB
H2L 4M1, Canada
2CRCHUM-Centre de recherché du Centre Hospitalier de l’Université de
Montréal, Montréal, Canada
© 2013 Chira et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orpatients received perioperative medication that could in-
fluence prostate swelling [1,4-6]. None of these studies
analyzed the clinical impact of prostate swelling.
The authors believe that knowing the intra-operative
extent of Pvol changes, its predictive factors, and the
post-operative impact of Pvol changes could help iden-
tify future patients who might need adjustments in plan-
ning to correct for prostate swelling. The present study
is the first analysis using 3 consecutive volume measure-
ments with TRUS to investigate risk factors for prostate
swelling as well as its clinical implications.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Study patients
A total of 149 consecutive patients with low- or inter-
mediate risk prostate carcinoma (≤T2b, Gleason score ≤ 7
and prostate-specific antigen ≤18) underwent prostate PB
as monotherapy using an intraoperative planning (IO) ap-
proach. No patient had received any antiandrogen therapy
before implantation. Patients were treated between Janu-
ary 2006 and February 2009 with 125-Iodine loose seed
implants, with a typical activity between 0.4-0.65 mCi,
without the addition of external beam radiation therapy.
The prescribed dose was 144 Gy in all cases. The study re-
ceived institutional review board approval of our hospital,
Notre-Dame Hospital, Montreal (CER 12.092).
Brachytherapy technique
The implant was realized using three-dimensional (3D)
ultrasound-guided (BKMedical Systems, Harlev, Denmark)
IO interactive planning with virtual needle guidance,
robotic seed delivery and needle retraction system (FIRST,
Nucletron, Veenendaal, The Netherlands). An IO 3D re-
constructed TRUS was done in extended dorsolithotomy
position with the patient under general or spinal anesthesia.
The complete implant planning and general guidelines
were described in a previous publication [7]. Patients were
told to stop anti-inflammatory drugs 10 days before the im-
plant. No perioperative cortisone was given. Before any
needles were inserted, a 3D-TRUS of the entire prostate
was done and saved. The prostate volume was contoured
after the implant, usually within 2 days after the procedure
on each 2.5 mm thick slice. This prostate volume was
defined as V1. Then another 3D-TRUS was done with 2
fixation needles inserted into the prostate. These needles
have a special harpoon to hold the prostate in place. Each
implant was done with the same model of fixation needles.
The prostate volume was contoured in the operating room
and defined as V2. The intra-operative dosimetry planning
of the implant was then done with V2. The planned tumorFigure 1 Example of TRUS (transrectal ultrasound) image acquisition
course of the implant (all in the operating room). Left image correspon
prostate volume after the insertion of 2 fixation needles (V2) and right imavolume consisted of the prostate gland with margins of 3
mm in all directions. Following completion of implant with
all seeds implanted, a third 3D-TRUS was done and saved,
and the prostate volume was contoured within the next 2
days and defined asV3 (Figure 1). Next, each patient under-
went a computed tomography (CT) scan usually at 30 days
after the implant (4 to 6 weeks) to evaluate implant quality
and dosimetry. The CT scan was performed with 3 mm
thick slices. All prostate contouring on TRUS and CT was
done by a single physician (DT). Seed localization was
performed using Nucletron FIRST integrated software Spot
Pro, version3.1. The D30 dosimetry was considered satis-
factory if the D90 (minimum dose in Grays received by 90%
of the prostate volume) was > 130 Gy. Urinary retention
was evaluated as the duration of catheterization following
the implant procedure. The duration was grouped into 3
categories: no immediate post-operative catheterization,
duration of 1–6 days and more than 7 days (includes self-
catheterization).
Statistical analysis
Descriptive analyses were performed to generate sum-
mary statistics. Correlations between clinical and im-
plant variables and differences in prostate volumes were
measured by Pearson correlation coefficient. The seed
activity variable was dichotomized as low (< 0.5 mCI)
and high (> = 0.5 mCi). Univariate and multivariate lin-
ear regression analyses were performed to determine
significant predictors of change in prostate volume. For
the multivariate analyses, all models included age and
baseline volume. Because at the time of measuring V1
the number of seeds, needles and seed activity were
irrelevant to V1, the models analyzing the difference be-
tween V3-V1 and V2-V1 did not include these factors.
Because the number of seeds and needles were highly
correlated, two models were estimated for the difference
in volume between V3 and V2; one included the number
of seeds and the other the number of needles.of the prostate (mid-gland) at 3 different time points during the
ds to baseline volume before the implant (V1), middle image to
ge to prostate after the completion of the implant (V3).
Table 1 Patient baseline characteristics
Characteristic Median (range)








PSA (ng/ml) 5.56 (0.88 - 18.46)
< 10 89.8%
≥10 10.2%
IPSS (baseline) 3 (0–24)
≤ 3 57.6%
>3 and ≤12 38.2%
>12 4.2%
Prostate baseline volume (cc) 36.8 (14.4-67.7)
No. of needles 23 (16–32)
No. of seeds 58 (38–94)
Activity (mCi) 0.59 (0.4-0.65)
High (≥0.5mCi) 54.4%
Low (<0.5mCi) 45.6%
No of seeds/needle 2.6 (1.9-3.8)
Abbreviations: TNM The American Joint Committee on Cancer staging, 7th
edition, 2009, PSA prostate-specific antigen, IPSS International Prostate
Symptom Score, cc cubic centimeters, mCi millicurie.
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ume (D90) at day 30 was analyzed as a continuous vari-
able and then as a dichotomous variable (< 130 Gy and
>130 Gy). Linear regression and logistic regression ana-
lyses were performed to analyze the influence of clinical
and implant factors on D90 at day D30. Because the differ-
ences in prostate volume between each step were highly
correlated, each multivariate analysis was modeled with
each difference in prostate volume separately (e.g. differ-
ence V2-V1 together with the clinical and implant factors,
then difference V3-V1 and other factors and finally V3-V2
and other factors). The limited number of patients with a
D90 at day 30 less than 130Gy prevented the fitting of a
model with a large number of variables. Therefore, these
models only included important variables such as the
difference in prostate volume, the baseline volume and the
source activity. The proportional odds model (POM) was
used to assess the influence of edema on the duration of
catheterization. A probability <0.05 was considered to be
statistically significant. Statistical program R 2.13.0 was
used for all data analysis (htpp://www.r-project.org).
Results
Prostate volume changes and its associated factors
Patient demographics and implant characteristics are
summarized in Table 1. Changes in prostate volume oc-
curring throughout the implant (V1 to V3), including in-
significant changes (< 5%) can be found in Table 2.
Mean baseline prostate volume (V1) was 37.4 ± 9.6 cc.
Fifty-one percent of patients had a volume increase of >
5% after the insertion of 2 fixation needles (V2). The
mean increase was 6.0% (SD 12.5%).
At the completion of the implant (V3), there was a fur-
ther increase by an average of 1.94 cc (SD 2.55cc) in Pvol
compared to V2. This corresponds to a mean increase of
4.5% (SD 5.5%). The total mean change in Pvol from be-
fore the implant before any manipulation (V1) to the end
of the implant (V3) was 10.3% (SD 12.6%) (Table 2).
Although the prostate swelling caused by insertion of
the fixation needles alone was larger than the one caused
by the implant itself, this did not reach statistical signifi-
cance (p = 0.23).
This might explain why in multivariate linear regression
results, baseline Pvol is predictive of Pvol changes be-
tween V2 and V1 and V3 and V1 but not between V3 and
V2. See Table 3 for univariate and multivariate analysis.
Influence of edema on implant quality parameter D90 on
day 30
Clinically, the extent of prostate swelling had an influ-
ence on D90. Table 4 presents the complete data.
The median D90 at Day 30 following the brachytherapy
was 158 Gy (range 105 to 236 Gy). Univariate logistic re-
gression using D90 as a dichotomized variable (model 1 ofD90: <130 vs. >130Gy) revealed that a Pvol change be-
tween V1 and V2 (OR 1.17, 95% CI, 1.02-1.37, p = 0.04)
were significantly associated with D90. An increase of 10%
in prostate volume between V1 and V2 results in an in-
crease of D90 at Day 30 by 11.7%.
When D90 was analyzed as a continuous variable
(model 2 for D90), both differences between V1-V2 (p =
0.0002) and V1-V3 (p = 0.001) were strongly associated
with D90.
An increase of 10% between V1 and V2 would have an
increase of the D90 at Day 30 by 14.6%.
Relationship between edema and urinary retention
A majority of patients (57.7%) did not require urinary
catheterization after the implant (group 1); 33.5% needed
1 to 6 days of catheterization (group 2), and 8.7% re-
quired either ≥ 7 days or auto-catheterization (2 weeks -
6 months) (group 3). The baseline prostate volume (V1)
was the only predictor of the duration of urinary reten-
tion in both univariate (p = 0.04) (not shown in table)
and multivariate regression analysis. Therefore, given all
other clinical characteristics are the same for 2 patients,
the one with 10% larger prostate volume at baseline
Table 2 Changes in prostate volume
Difference in percent Difference in cc
Δ 2-1 Δ 3-2 Δ 3-1 Δ 2-1 Δ 3-2 Δ 3-1
Increase*
Total 70.7 85.9 82.1 Mean (SD) 2.51 (5.1) 1.94 (2.55) 4.46 (5.54)
<5%* 20.0 43.6 10.7 Median 2.0 1.66 4.25
>5%* 50.7 42.3 71.4 IQR −0.32-4.77 0.56-2.99 1.43-7.20
Mean in cc (SD) 6.0 (12.5) 4.5 (5.5) 10.3 (12.6)
Decrease*
Total 29.3 14.1 17.9 Decreasing mean (SD) −2.49 (2.73) −1.47 (1.54) −2.79 (2.65)
<5%* 16.4 10.7 10.8 Increasing mean (SD) 4.56 (4.33) 2.48 (2.25) 6.04 (4.68)
>5%* 12.9 3.4 7.1
*Increase/decrease in percentage of patients.
Abbreviations: cc cubic centimeters, Δ 2–1 difference between volumes 2 and 1, Δ 3-2 difference between volumes 3 and 2, Δ 3-1 difference between volumes 3
and 1, SD standard deviation, IQR interquartile range.
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to a higher retention group (Table 5).
Discussion
Little is known about the incidence of prostate edema
(PE) during prostate brachytherapy and its risk factors.
Although its course following the implant was docu-
mented [8,9], little can be done to improve dosimetry
after the patient left the operating room. With that in
mind, the objective of the present study was to evaluate
changes in prostate volume in the operating room before
and at the time of the completion of the implant. This
study consistently used 3D-TRUS measurements of the
prostate to eliminate uncertainties from combining dif-
ferent imaging modalities.
In this present study, we considered changes ≤ 5% in
prostate volume as insignificant. This is in accordance
with Liu et al. [10] who found the intraobserver variabil-





Δ V2 - V1 Baseline volume −0.18 (−0.27/-0.10)
Age −0.05 (−0.19/0.07)
Δ V3 - V1 Baseline volume −0.16 (−0.25/-0.07)
Age −0.05 (−0.19/0.10)




No. of seeds 0.03 (−0.002/0.06)
No. of needles 0.12(0.018/0.23)
Abbreviations: CI confidence intervals, Δ 2–1 difference between volumes 2 and 1, Δ
and 1, SD standard deviation, IQR interquartile range. * bold when p < 0.05.volume of 39.6 cc. In addition, we believe that a small
difference in prostate volume would be clinically
insignificant.
The most surprising finding in this study was first that
prostate volumes increase by > 5% were seen more often
after the insertion of fixation needles (50.7%) than after
the insertion of all the radioactive sources (42.3%). And
second that the mean difference in prostate volume was
between V1 and V2 (2.51 cc) and V2 and V3 (1.94 cc),
was not significant (p = 0.2).
We believe that the present study is the first to analyze
prostate volume changes on three different time-points
by the same imaging modality during the course of a
permanent seed implant in a relatively large number of
patients compared to other similar studies. Martinez
et al. [11] in a prospective study of high dose rate (HDR)
interstitial brachytherapy in 41 patients, found, similar
to our data, that the largest increase in prostate volume
occurred shortly after the insertion of needles (beforelume difference
Multivariate analysis
CI) P value* Correlation coefficient (95% CI) P value
<0.0001 −0.18 (−0.27/-0.10) <0.0001
0.38 −0.005 (−0.13/0.12) 0.94
<0.001 −0.16 (−0.26/-0.07) 0.001
0.51 −0.001 (−0.15/0.14) 0.99
0.30 0.006 (−0.05/0.06) 0.82
0.85 −0.002 (−0.07/0.07) 0.94
0.77 - -
0.21 −0.11 (−1.3/1.06) 0.84
0.07 0.03 (−0.01/0.07) 0.18
0.02 0.11 (−0.05/0.28) 0.16
3-2 difference between volumes 3 and 2, Δ 3-1 difference between volumes 3
Table 4 Multivariate logistic analysis for D90 at Day 30 as dichotomized variable (model 1: D90 >130 vs. <130 Gy)
Factor Multivariate analysis
Model with edema between Odds ratio 95% CI P value*
Δ V2 – V1 Baseline volume 1.02 0.96 1.09 0.51
Age - - - -
Source activity 1.49 0.47 4.92 0.50
V2-V1 1.17 1.02 1.37 0.038
Δ V3 – V1 Baseline volume 1.00 0.95 1.06 0.94
Age - - - -
Source activity 1.76 0.57 5.69 0.32
V3-V1 1.06 0.95 1.20 0.31
Δ V3 – V2 Baseline volume 1.00 0.94 1.06 0.99
Age - - - -
Source activity 1.61 0.51 5.25 0.41
Nr of seeds - - - -
Nr of needles - - - -
V3-V2 0.87 0.72 1.05 0.12
Abbreviations: D90 minimum dose received by 90% of prostate volume at Day 30, Δ V2-V1 difference between volumes 2 and 1, Δ V3-V2 difference between
volumes 3 and 2, Δ V3-V1 difference between volumes 3 and 1, CI confidence intervals.* bold when p < 0.05.
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trauma. Interestingly, 28.6% of our patients did not experi-
ence >5% increase in prostate volume between V1 and V3.
There are many possible explanations for this finding.
For one, there is interobserver variability, which we
didn’t measure in this study but has been shown by Liu
et al. [10] to be at a mean of 9.3%. Prostate volume can
also depend on where to start and end prostate
contouring. The starting slice in our study was not set at
a specific point. This decrease could be due to a deform-
ation of the prostate that resulted in a falsely measured
decrease in Pvol. Volume changes due to the insertion
of the fixation needles and the radioactive seeds are
small and account for less than 1% of the change in Pvol
between V2 and V3.
Applying different pressure with the TRUS-probe at the
different measuring points on the prostate can causeTable 5 Proportional odds model for urinary retention
Model with edema between Factor
ΔV2 – V1 Baseline volume
Source activity
V2-V1
ΔV3 – V1 Baseline volume
Source activity
V3-V1
ΔV3 – V2 Baseline volume
Source activity
V3-V2
Abbreviations: OR the odds ratio, CI confidence intervals, V1 baseline volume, V2 vol
implant.* bold when p < 0.05.indentation that can deform the prostate and cause
changes in prostate contouring [10]. Another important
point is that the seeds in the prostate can cause artifacts
that make prostate volume definition difficult. Post-
implant TRUS has been shown to have a higher intra-
observer variability compared with MRI, as reviewed by
Liu et al. [10]. This could explain why there is so little
change in prostate volume between the implant of the 2 fix-
ation needles (V2) and the completion of the implant (V3).
On the other hand, our data are supported by Smith
et al. [12] who showed, measured with TRUS, an increase
of 18% in prostate volume with the implant of the needles,
before seed delivery.
Another explanation for a lack of significant Pvol
changes is that there might be individual differences in
response of prostate and peri-prostatic tissue to mechan-
ical injury. The present results showed that the extent ofOdds ratio 95% CI P value*
1.04 0.99 1.07 0.063
0.94 0.48 1.84 0.86
1.00 0.93 1.07 0.91
1.04 1.00 1.08 0.032
0.93 0.48 1.82 0.83
1.01 0.96 1.08 0.57
1.04 1.00 1.07 0.052
0.98 0.50 1.94 0.96
1.09 0.96 1.24 0.19
ume after insertion of 2 fixation needles, V3 volume at the completion of the
Chira et al. Radiation Oncology 2013, 8:177 Page 6 of 7
http://www.ro-journal.com/content/8/1/177Pvol changes is mainly dependent of baseline prostate
volume: the smaller the prostate, the larger the edema.
This confirms the results from other studies. Chung
et al. [13] demonstrated that small prostates (≤ 25 ml)
have the greatest post-implant edema compared to lar-
ger ones, even though they argued that this might be the
result of an overestimation of prostate volume at the
time of the implant. Using CT-MRI fusion on the day of
implant, on Day 8 and 30, Taussky et al. [14] reported
that smaller prostates (<35 ml) show a proportionally
greater increase in volume than do larger ones as well.
Edema can have an influence on implant quality and
can cause suboptimal implants [14]. Biochemical outcome
had been linked to D90 in several published reports of
prostate brachytherapy [15,16]. In a study by Zelefsky and
collegues, a threshold of ≥130 Gy was used to define a sat-
isfactory implant [17]. Our results showed that an increase
of 10% in edema between V1-V2 increases 4.79 times the
chance of a D90 to be >130 Gy. This on first sight coun-
terintuitive result may simply be due to the fact that only
16 patients (10.7%) of the study group had a D90 value
<130 Gy. On the other hand, we believe this is due to the
fact that the prostate volume used for implant planning
(V2) overestimates the volume compared to at D30, be-
cause it has already experienced a large part of the PE due
to the implant of the fixation needles.
We further found that an increase in prostate volume
between V1 and V2 by only 10% (less than 1 SD) could
increase the risk for longer duration of AUR by 48% on
average. Baseline prostate volume, but not the extent of
PE, was the only factor associated with the duration of
AUR. Unfortunately, data on the dose to the urethra are
not available to measure their possible influence on urin-
ary retention. Rates of AUR vary in the literature
between 5.6% [18] to 34% [19]. In our data 33.5% of pa-
tients required short-term catheterization (1 to 6 days)
while only 8.7% needed long-term catheterization (≥ 7
days). No cut-off level could be identified to predict for
a larger difference between V1 and V2 and therefore an
increase in AUR. We found that the larger the baseline
prostate volume the longer duration of catheterization.
This corroborates with findings from prior single-
institution experience. Thus, Crook et al. [20] also found
that a large prostate volume at the time of implant was
independently associated with AUR. Our results cannot
be applied generally. Our outpatient unit closes relatively
early in the evening (8 PM), giving patients implanted
later in the day little time to urinate before they have to
be discharged. Taking this into consideration, the per-
centage of patients needing catheterization >1 day (in
over 700 patients implanted so far) is only about 8%,
which is comparable to the literature.
Findings of the present study raised several intriguing
clinical implications. First, because relatively little traumato the prostate associated with the insertion of fixation
needles causes the majority of PE, we suggest to plan the
implant after the insertion of the fixation needles or to
add a larger PTV margins if planned without this initial
trauma. Although we didn’t compare dosimetry at D90 for
prostates planned with or without fixation needles, we be-
lieve that fixation needles can help to reduce margins
added to compensate for PE and could therefore help to
improve implant quality and reduce doses to organs at
risk. It could be especially helpful to add larger margins to
smaller prostates. This added margin could represent an
increase in volume of 10.3% (1 SD in difference between
V1 and V3) for larger prostates and for smaller prostates
up to 20.6% (2 SD).
Second, the use of anti-inflammatory treatment, especially
for small prostates should be further explored. Feigenberg
et al. [21] showed that the use of cyclooxygenase-2 (COX-2)
inhibitor therapy 1 week before the implant decreased the
risk of urinary retention. These findings were also sup-
ported by Sacco et al. [22] in a retrospective series of pa-
tients using a 2-week course of dexamethasone started
after the implant. However, the negative results from a
phase III trial of a 4-week course of COX-2 inhibitor ther-
apy (starting either on the day of implant or 1 week prior
to implant) did not support this preventive approach. Even
if this matter remains inconclusive, none of these studies
investigated sub-groups of patients, such as patients with
smaller prostates.
We believe that more research into the reduction of
PE would not only be beneficial for implant quality but
also reduce the duration of AUR.
This study has several limitations that could affect its
interpretation. First, this is a retrospective series, thus
possibility of bias in patient selection is unknown and
cannot be assessed. Second, although this study showed
that fixation needle-associated PE is predictive of D90,
this study lacks TRUS prostate volume measurements at
day 30.
Conclusions
Smaller prostates have larger PE. The insertion of 2 fix-
ation needles with a harpoon causes at least as much PE
than the implant of the radioactive seeds. Therefore, in
centers using pre-planning techniques careful conside-
ration should be given to planning volume in order to
compensate for prostate volume differences occurring in
the operating room. Furthermore, we need to know more
about what causes PE and how to prevent it.
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